Developing Patient-Derived 3D-Bioprinting Models of Pancreatic Cancer

This study developed patient-derived 3D-bioprinting models of pancreatic cancer (PC) involving 23 patients, with successful model creation for 20. These models replicate the tumor microenvironment and maintain the histological and genomic characteristics of the original tumors. They showed a strong correlation between chemotherapy drug responses and actual clinical outcomes, suggesting their potential for predicting effective treatments. The models capture individual tumor heterogeneity, offering a promising approach for personalized PC therapy. They provide personalized drug response data and have advantages over traditional methods, such as cost-effectiveness and rapid construction, although they require large tumor samples. The findings indicate these models could be valuable for drug screening and prognostic predictions, advancing precision-oriented therapeutic strategies for PC.